Saul Faust
Impact in
- Infectious Diseases top 0.02%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Health top 0.1%
- Vaccine Coverage and Hesitancy
Papers in
- Microbiology 58
- Bacterial Infections and Vaccines 56
- Epidemiology 112
- Pneumonia and Respiratory Infections 62
- Respiratory viral infections research 32
- Influenza Virus Research Studies 20
- Sepsis Diagnosis and Treatment 18
- Co-authors
- Alasdair Peter Stuart Munro (11 shared papers)Michael L. Levin (16 shared papers)Stuart C. Clarke (32 shared papers)Robert Heyderman (6 shared papers)Johanna M. Jefferies (22 shared papers)Odile Barbara Harrison (2 shared papers)Robert David Goldin (2 shared papers)Zoltan G. Laszik (1 shared paper)
- Journals
- The Lancet (17 papers)The Pediatric Infectious Disease Journal (15 papers)Journal of Infection (13 papers)Archives of Disease in Childhood (11 papers)Vaccine (10 papers)
- Partner nations
- United KingdomUnited StatesAustralia
In The Last Decade
Saul Faust
294 papers receiving 27.8k citations
Saul Faust's Hit Papers
Peers
Comparison fields: 5 of 183
- Infectious Diseases 13.6k
- Health 2.0k
- Modeling and Simulation 1.0k
- Microbiology 1.3k
- Neurology 3.0k
Countries citing papers authored by Saul Faust
This map shows the geographic impact of Saul Faust's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saul Faust with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saul Faust more than expected).
Fields of papers citing papers by Saul Faust
This network shows the impact of papers produced by Saul Faust. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saul Faust. The network helps show where Saul Faust may publish in the future.
Co-authors
The 25 scholars most cited alongside Saul Faust, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 311 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dexamethasone in Hospitalized Patients with Covid-19. Hit paper breakdown → | 2020 | 6645 |
| 2 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Hit paper breakdown → | 2020 | 3621 |
| 3 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Hit paper breakdown → | 2020 | 1899 |
| 4 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Hit paper breakdown → | 2021 | 867 |
| 5 | Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children Hit paper breakdown → | 2020 | 834 |
| 6 | 2001 | 540 | |
| 7 | 2020 | 519 | |
| 8 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Hit paper breakdown → | 2020 | 505 |
| 9 | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 Hit paper breakdown → | 2021 | 501 |
| 10 | Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Hit paper breakdown → | 2021 | 465 |
| 11 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 12 | Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children Hit paper breakdown → | 2020 | 403 |
| 13 | Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial Hit paper breakdown → | 2021 | 395 |
| 14 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 15 | 2016 | 362 | |
| 16 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 17 | A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process Hit paper breakdown → | 2020 | 257 |
| 18 | Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants Hit paper breakdown → | 2023 | 253 |
| 19 | 2014 | 247 | |
| 20 | 2016 | 242 |
About Saul Faust
Saul Faust is a scholar working on Microbiology, Epidemiology, Infectious Diseases, Public Health, Environmental and Occupational Health and Immunology, having authored 311 papers that have together received 28.7k indexed citations. Recurring topics across this work include Pneumonia and Respiratory Infections (62 papers), Bacterial Infections and Vaccines (56 papers), SARS-CoV-2 and COVID-19 Research (39 papers), Respiratory viral infections research (32 papers), Influenza Virus Research Studies (20 papers), Sepsis Diagnosis and Treatment (18 papers), Immunodeficiency and Autoimmune Disorders (12 papers) and Streptococcal Infections and Treatments (12 papers). The work is most often cited by research in Infectious Diseases (13.6k citations), Health (2.0k citations), Modeling and Simulation (1.0k citations), Microbiology (1.3k citations) and Neurology (3.0k citations). Saul Faust has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Alasdair Peter Stuart Munro, Michael L. Levin, Stuart C. Clarke, Robert Heyderman, Johanna M. Jefferies, Odile Barbara Harrison, Robert David Goldin, Zoltan G. Laszik, Charles T. Esmon and Rebecca Ashley Gladstone. Their work appears in journals such as The Lancet, The Pediatric Infectious Disease Journal, Journal of Infection, Archives of Disease in Childhood and Vaccine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.